IceCure Medical Ltd. (NASDAQ: ICCM) announced the appointment of Meir Peleg as Chief Financial Officer, effective May 17, 2026, according to a company statement.

Peleg brings over 20 years of financial leadership experience, including work with Nasdaq-listed companies. He has led a Nasdaq IPO and multiple capital raises while scaling organizations to more than 700 employees worldwide. Peleg holds an MBA and BA in Economics and Computer Science from Bar-Ilan University and is a Certified Public Accountant in Israel.

The company also plans to appoint Richard E. Fine, MD, FACS as Medical Director in the second quarter of 2026 to lead breast indications. Fine is a breast surgical oncologist and Director of the Breast Program at the Margaret West Comprehensive Breast Center at West Cancer Center & Research Institute in Germantown, Tennessee.

IceCure initiated a search for a new Chief Technology Officer following the departure of Naum Muchnik, Vice President of R&D and Engineering, effective April 12, 2026.

The appointments come as IceCure reports commercial momentum for its ProSense system following FDA clearance for low-risk breast cancer treatment and a recommendation from the American Society of Breast Surgeons for cryoablation use in select patients.

IceCure develops cryoablation technology that destroys tumors by freezing. The ProSense system received FDA marketing authorization for local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above.